| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 24020 |
| Drug | Sparsentan |
| Brand | Filspari® |
| Indication | For the treatment of adults with primary immunoglobulin A (IgA) nephropathy with a urine protein excretion >1.0 g/day (or urine protein-to-creatine ratio ≥0.75 g/g). |
| Assessment Process | |
| Rapid review commissioned | 30/05/2024 |
| Rapid review completed | 26/06/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sparsentan compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/07/2024 |
| Pre-submission consultation with Applicant | 01/10/2024 |
